Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2020 Apr)
Early detection by screening significantly reduces mortality from colorectal cancer, but 40% of guideline-eligible patients are not screened as recommended in the US. Novel strategies to improve screening uptake overall, and efforts to deploy best-practices to underserved populations is a high priority for healthcare. This review focuses on existing biomarkers in practice and those in development with clinical relevance to early detection of colorectal neoplasia, with an emphasis on those developed by investigators of the National Cancer Institute’s Early Detection Research Network (EDRN). Aberrantly methylated DNA markers (blood and stool), stool-based markers (including FIT-DNA), and a variety of blood-based markers assays in development (protein markers, glycoproteins including mucins, cell-free DNA tests) are reviewed. Individual markers and biomarker panels, sample resources, and barriers to translating biomarkers to clinical practice are discussed.
Forfattere: Bresalier RS, Grady WM, Markowitz SD, Nielsen HJ, Batra SK, Lampe PD